Literature DB >> 11716993

Mammographic density increase in women receiving different hormone replacement regimens.

C T Erel1, G Esen, H Seyisoglu, K Elter, C Uras, E Ertungealp, M F Aksu.   

Abstract

OBJECTIVE: we investigated effects of different regimens of hormone replacement therapy (HRT) on mammographic density.
METHODS: ninety-five postmenopausal women, who were on different HRT regimens and completed their 4-year mammographic follow-up, were included into this retrospective and comparative study. Twenty-three of these women, who had surgical menopause, received conjugated equine estrogens (CEE) (Group I) only, 26 of them received CEE and continuous medroxyprogesterone acetate (MPA) (Group II), 21 women received CEE and cyclic MPA (Group III), and the remaining 25 women received tibolone (Group IV) therapy. Before commencing on HRT, a baseline high-resolution mammography was performed, and repeated at 6-12-month intervals during the period of 4-year follow-up. All mammographies were evaluated according to the Wolfe classification.
RESULTS: a diffuse increase in mammographic density was detected in five women (22%) in group I, nine women (35%) in group II, four women (19%) in group III, and two women (8%) in group IV. The increase in mammographic density was more common among women in group II than those in the other three groups. However, a statistically significant difference was found only between groups II and IV.
CONCLUSIONS: different HRT regimens have different effects on breast parenchymal density on mammography. Continuous combination HRT may be more commonly associated with an increase in breast density than other forms of HRT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716993     DOI: 10.1016/s0378-5122(01)00236-5

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  8 in total

Review 1.  Physical activity and mammographic breast density: a systematic review.

Authors:  Lusine Yaghjyan; Graham A Colditz; Kathleen Wolin
Journal:  Breast Cancer Res Treat       Date:  2012-07-20       Impact factor: 4.872

Review 2.  Tibolone and breast cancer.

Authors:  C Tamer Erel; Levent M Senturk; Semih Kaleli
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

3.  Short-term hormone therapy suspension and mammography recall: a randomized trial.

Authors:  Diana S M Buist; Melissa L Anderson; Susan D Reed; Erin J Aiello Bowles; E Dawn Fitzgibbons; Juleann C Gandara; Deborah Seger; Katherine M Newton
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

4.  Relationship between breast cancer risk factors and mammographic breast density in the Fernald Community Cohort.

Authors:  L Yaghjyan; M C Mahoney; P Succop; R Wones; J Buckholz; S M Pinney
Journal:  Br J Cancer       Date:  2012-01-26       Impact factor: 7.640

Review 5.  Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies.

Authors:  Catherine Schairer
Journal:  Breast Cancer Res       Date:  2002-10-07       Impact factor: 6.466

6.  Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study.

Authors:  Shadi Azam; Theis Lange; Stephanie Huynh; Arja R Aro; My von Euler-Chelpin; Ilse Vejborg; Anne Tjønneland; Elsebeth Lynge; Zorana J Andersen
Journal:  Cancer Causes Control       Date:  2018-04-18       Impact factor: 2.506

Review 7.  The epidemiologic factors associated with breast density: A review.

Authors:  Dong-Man Ye; Tao Yu
Journal:  J Res Med Sci       Date:  2022-07-29       Impact factor: 1.985

Review 8.  Postmenopausal hormone therapy and breast cancer: a clinician's message for patients.

Authors:  Leon Speroff
Journal:  Endocrine       Date:  2004-08       Impact factor: 3.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.